INOTEK PHARMACEUTICALS CORP's ticker is ITEK and the CUSIP is 45780V102. A total of 35 filers reported holding INOTEK PHARMACEUTICALS CORP in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $5,220,000 | +95.5% | 2,000,000 | +33.3% | 0.01% | +100.0% |
| Q3 2017 | $2,670,000 | +199.0% | 1,500,000 | +219.1% | 0.01% | +200.0% |
| Q2 2017 | $893,000 | -5.0% | 470,000 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $940,000 | -67.2% | 470,000 | 0.0% | 0.00% | -75.0% |
| Q4 2016 | $2,867,000 | -35.7% | 470,000 | 0.0% | 0.01% | -33.3% |
| Q3 2016 | $4,456,000 | +27.4% | 470,000 | 0.0% | 0.01% | +20.0% |
| Q2 2016 | $3,497,000 | +71.8% | 470,000 | +70.9% | 0.01% | +66.7% |
| Q1 2016 | $2,035,000 | -34.7% | 275,000 | 0.0% | 0.01% | -25.0% |
| Q4 2015 | $3,116,000 | +20.5% | 275,000 | 0.0% | 0.01% | +14.3% |
| Q3 2015 | $2,585,000 | – | 275,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Devon Park Associates, LLC | 3,243,709 | $24,133,000 | 100.00% |
| RHO CAPITAL PARTNERS INC | 2,627,790 | $19,551,000 | 15.64% |
| FT Options LLC | 144,751 | $1,077,000 | 0.92% |
| SENZAR ASSET MANAGEMENT, LLC | 445,022 | $3,310,964,000 | 0.72% |
| SPHERA FUNDS MANAGEMENT LTD. | 250,000 | $1,860,000 | 0.48% |
| PURA VIDA INVESTMENTS, LLC | 75,000 | $558,000 | 0.24% |
| Orbimed Advisors | 1,391,000 | $10,349,000 | 0.11% |
| SHEPHERD KAPLAN KROCHUK, LLC | 57,344 | $427,000 | 0.11% |
| EverPoint Asset Management, LLC | 555,528 | $4,133,000 | 0.08% |
| TFS CAPITAL LLC | 56,936 | $424,000 | 0.08% |